Table 3.
Clinical outcomes
| Total (n = 150) | Non-survivor (n = 31) | Survivor (n = 119) | P-Value | |
|---|---|---|---|---|
| Complication, n (%) | ||||
| Sepsis | 56 (37.3%) | 31 (100.0%) | 25 (21.0%) | <0.001 |
| Septic shock | 19 (12.7%) | 19 (61.3%) | 0 (0.0%) | <0.001 |
| Respiratory failure | 40 (26.7%) | 29 (93.5%) | 11 (9.2%) | <0.001 |
| ARDS | 26 (17.3%) | 26 (83.9%) | 0 (0.0%) | <0.001 |
| Acute cardiac injury | 15 (10.0%) | 15 (48.4%) | 0 (0.0%) | <0.001 |
| Heart failure | 13 (8.7%) | 12 (38.7%) | 1 (0.8%) | <0.001 |
| Acute kidney injury | 21 (14.0%) | 19 (61.3%) | 2 (1.7%) | <0.001 |
| Acidosis | 20 (13.3%) | 20 (64.5%) | 0 (0.0%) | <0.001 |
| Hypoproteinemia | 20 (13.3%) | 18 (58.1%) | 2 (1.7%) | <0.001 |
| Coagulopathy | 26 (17.3%) | 24 (77.4%) | 2 (1.7%) | <0.001 |
| Time from illness onset to respiratory failure, days | 9 (6.3-11) | 9 (7-10) | 6 (3-17) | 0.637 |
| Time from illness onset to ARDS, days | – | 10.5 (9-12) | – | – |
| Time from illness onset to septic shock, days | – | 18 (14-23) | – | – |
| Time from illness onset to acute kidney injury, days | – | 16 (10-22) | – | – |
| Time from illness onset to death or discharge, days | 24 (18-30) | 22 (13-25) | 25 (19-30) | 0.019 |
| Hospital length of stay, days | 16 (12-21) | 13 (6-17) | 17 (12-23) | 0.002 |
| Duration of viral shedding after COVID-19 onset, days | 7 (4-10) | 12 (7.8-15) | 6 (4-10) | <0.001 |
Abbreviations: ARDS, acute respiratory distress syndrome.